Clinical trials: Pre-eclampsia
Low Birth Weight, Small for Gestational Age (SGA)
Improving Aspirin Prescription Rates in Outpatient Clinic
Ρrееςlаmpѕia is a syndrome characterised by the new onset of hуреrtеnѕion plus proteinuria, end-organ dysfunction, or both after 20 weeks of gestation. It complicates 3-5% of pregnancies.
- Conditions
- Low Birth Weight, Small for Gestational Age (SGA), Preeclampsia (PE), Prevention &Amp; Control
- Trial name
- NCT06694233
- Testing
- Aspirin prescription on outpatient basis
- Where
- Kuwait
- Volunteers
- 300 people
- Sponsor
- Cairo University
Preeclampsia
Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Survey
To determine if women can understand the instructions, carry out the test, and interpret the test results. Women will be recruited to complete a test instruction and comprehension assessment and a usability assessment.
- Trial name
- NCT02611011
- Testing
- Congo Red Test (GV-005)
- Where
- Mexico
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Gynuity Health Projects
Preeclampsia, Anxiety
Comparing Different Methods of Patient Education on Preeclampsia
Preeclampsia is a life-threatening condition unique to pregnancy which occurs in 5-8% of all pregnancies. It contributes to a large proportion of maternal mortality worldwide and these deaths largely result from delayed…
- Conditions
- Preeclampsia, Anxiety, Hypertension, Pregnancy
- Trial name
- NCT02765906
- Testing
- Graphic card, Video
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
Preeclampsia
Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)
Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)
- Trial name
- PHP3 (NCT02221830)
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Colorado, Denver
Pre-Eclampsia, Cardiovascular Diseases
Pre-eclampsia and Future Cardiovascular Health: An Underused Opportunity to Improve Family Health
Background: PE (pre-eclampsia) is a common pregnancy-specific vascular hypertensive disease affecting 3-5% of pregnancies. PE independently increases the risk for premature cardiovascular disease (CVD) in mothers and their…
- Conditions
- Pre-Eclampsia, Cardiovascular Diseases, Cardiovascular Risk Factor, Gestational Hypertension
- Trial name
- FINNCARE (NCT04676295)
- Testing
- Face-to-face and web-based lifestyle intervention
- Where
- Finland
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Hypertension, Pregnancy Induced, Hydralazine Adverse Reaction
Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.
Severe Hypertension in pregnancy demands urgent treatment because of high mortality \& morbidity in obstetric patients. Hydralazine, the most commonly used agent, causes sudden hypo tension and tachycardia.
- Conditions
- Hypertension, Pregnancy Induced, Hydralazine Adverse Reaction, Pre-eclampsia, Pre-eclampsia Superimposed Pre-existing Hypertension
- Trial name
- NCT02050529
- Testing
- Labetalol, Hydralazine
- Where
- Pakistan
- Volunteers
- 190 people
- Sponsor
- Dow University of Health Sciences
Preeclampsia, Intrauterine Growth Restriction
First Trimester Placental Assessment in the Screening of Preeclampsia and Intrauterine Growth Restriction
Preeclampsia (PE) and intrauterine growth restriction (IUGR) are clinical manifestations of placental insufficiency. These complications affect 5-15% of pregnancies, and are responsible for up to 20% of preterm births.
- Trial name
- NCT02879942
- Testing
- Ultrasound study of the placenta, Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test
- Where
- Spain
- Volunteers
- 1,390 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Preeclampsia, Pregnancy
Aspirin Role for Preventing Clinical Risks Related to High Risk Pregnancy
Preeclampsia and its related consequences significantly contribute to maternal and neonatal morbidity and mortality, particularly in high-risk pregnancies.
- Trial name
- NCT07087067
- Testing
- Aspirin 75 mg
- Where
- Egypt
- Volunteers
- 87 people
- Sponsor
- Galala University
Preeclampsia
PP13 and Doppler Study to Predict Preeclampsia
Assessment of biochemical and sonographic marker to predict the risk for developing preeclampsia Among biochemical markers are serum level of Placental Protein 13 (PP13) and Placenta Growth factor (PIGF).
- Trial name
- NCT00928213
- Testing
- Progesterone, Low molecular weight Heparin, No Drug
- Where
- Israel
- Volunteers
- 1,000 people
- Sponsor
- Ben-Gurion University of the Negev
Preeclampsia
Family Study on Preeclampsia
This study will examine a possible genetic basis for preeclampsia, a disorder of high blood pressure and protein in the urine during pregnancy. Preeclampsia is a major pregnancy complication affecting both mother and baby.
- Trial name
- NCT00344162
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Pre-Eclampsia, Eclampsia
Catestatin and Hypertension in Pregnancy
Catestatin is a kind of protein involved with cardiovascular disease. Accumulated evidence shows that Catestatin may be a predictor of primary hypertension, but whether it plays the same role in pregnant hypertensive disorders…
- Conditions
- Pre-Eclampsia, Eclampsia, Hypertension, Pregnancy-Induced, Hypertension in Pregnancy
- Trial name
- NCT03200743
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Yuchen Pan
Preeclampsia, Eclampsia
uChek Pilot Study for Urinalysis in the Antenatal Care Setting
A prospective observational study to test the feasibility of smartphone enabled uChek urinalysis device to detect biomarkers (protein, microalbumin and protein:creatine ratio) in urine, indicative of preeclampsia/eclampsia at…
- Conditions
- Preeclampsia, Eclampsia, Pregnancy, Proteinuria
- Trial name
- uChekBangla (NCT02256995)
- Testing
- uChek
- Where
- Bangladesh
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Maternova Research
Preeclampsia
Progesterone in Expectantly Managed Early-onset Preeclampsia
Preeclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation and can present as late as 4-6 weeks postpartum
- Trial name
- NCT04077853
- Testing
- 17 Hydroxyprogesterone Capronate
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Pre-Eclampsia
Safety and Efficacy of Twelve Hours Duration of MgSO4 in the Treatment of Eclampsia in Low Resource Setting in Sudan
the investigators assume that magnesium sulphate for treating eclampsia can be safely reduced from 24 hours to shorter duration of therapeutic anticonvulsant effect for 12 hours.
- Trial name
- NCT03112551
- Testing
- Adminstration of magnesium Sulphate for treatment of eclampsia
- Where
- Sudan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gadarif University
Pre-Eclampsia; Complicating Pregnancy, Antiphospholipid Syndrome in Pregnancy
Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure
The primary goal of this observational study is to learn about postpartum pulmonary artery pressure in women who suffered from Preeclampsia and Antiphospholipid Syndrome.
- Conditions
- Pre-Eclampsia; Complicating Pregnancy, Antiphospholipid Syndrome in Pregnancy, Pulmonary Hypertension
- Trial name
- NCT05679206
- Testing
- Echocardiography images, 24-hour ambulatory blood pressure monitoring
- Where
- Switzerland
- Volunteers
- 900 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Preeclampsia
Cornell University-Micronutrient Initiative Calcium Supplementation Study
The World Health Organization (WHO) now recommends prenatal calcium supplementation for prevention of preeclampsia in populations with inadequate dietary intake.
- Trial name
- MICA (NCT02238704)
- Testing
- Regimen A calcium and iron/folic acid, Regimen B calcium and iron/folic acid
- Where
- 16 sites in Kenya
- Volunteers
- 1,032 people, healthy volunteers welcome
- Sponsor
- Cornell University
Thrombocytopenia, Small for Gestational Age (SGA)
Mechanism of Thrombocytopenia in Infants
This research project is studying the causes for low platelet levels in preterm infants. Platelets are a component of blood that helps with clotting.
- Conditions
- Thrombocytopenia, Small for Gestational Age (SGA), Preeclampsia
- Trial name
- NCT00333333
- Testing
- Cord blood
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Christiana Care Health Services
Preeclampsia, Pregnancy Induced Hypertension
Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial
Eclampsia is a major cause of perinatal morbidity and mortality. The pathophysiology is not known but magnetic resonance imaging (MRI) and Doppler data suggest that overperfusion of the cerebral tissues is a major etiologic…
- Conditions
- Preeclampsia, Pregnancy Induced Hypertension, Gestational Hypertension, Chronic Hypertension
- Trial name
- LAMPET (NCT00293735)
- Testing
- labetalol (seizure prevention), MgSO4 (seizure prevention)
- Where
- 2 sites in United States, India
- Sponsor
- Baylor College of Medicine
Pregnancy
PLAC1 in Reproduction
The PLAC1 gene is a recently described X-linked gene that maps to a region of the X chromosome thought to be important for normal fetal and placental development.
- Trial name
- NCT01277848
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Hypertension, Morality
Mortality Outcome of Controlled Hypertension
This review focuses on the assumption of mortality outcome of participants remaining label hypertension care is adequately managed when pressure targets are met with both qualitative and quantitaive method.
- Conditions
- Hypertension, Morality, Death, Pre-Eclampsia
- Trial name
- MOCH1 (NCT07187596)
- Where
- Thailand
- Volunteers
- 2,547 people
- Sponsor
- DejthidaNathaphong